Patents by Inventor Paul R. Hinton
Paul R. Hinton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076392Abstract: This disclosure provides an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD123. Also provided are polynucleotides encoding the antibody or antigen-binding fragment or derivative thereof and vectors and host cell comprising said polynucleotides. This disclosure further provides methods for producing and/or using an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD123.Type: ApplicationFiled: February 17, 2022Publication date: March 7, 2024Inventors: Paul R. HINTON, Manal AMOURY
-
Publication number: 20230058162Abstract: This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).Type: ApplicationFiled: July 27, 2021Publication date: February 23, 2023Inventors: Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
-
Publication number: 20220403009Abstract: This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).Type: ApplicationFiled: July 14, 2022Publication date: December 22, 2022Inventors: Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
-
Patent number: 11344621Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: August 27, 2018Date of Patent: May 31, 2022Assignee: Abbvie, Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Publication number: 20200308290Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.Type: ApplicationFiled: June 11, 2020Publication date: October 1, 2020Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
-
Publication number: 20190008966Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: August 27, 2018Publication date: January 10, 2019Applicant: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Patent number: 10150814Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.Type: GrantFiled: June 25, 2014Date of Patent: December 11, 2018Assignee: AbbVie Biotherapeutics Inc.Inventors: Paul R. Hinton, Veronica Juan
-
Patent number: 10086076Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: March 13, 2017Date of Patent: October 2, 2018Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Publication number: 20180251565Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.Type: ApplicationFiled: February 22, 2018Publication date: September 6, 2018Inventors: Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
-
Publication number: 20170340737Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: March 13, 2017Publication date: November 30, 2017Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Hua YING, Maria A. ARGIRIADI, Carolyn A. CUFF, Paul R. HINTON, Shankar KUMAR, Terry L. MELIM, Yan CHEN
-
Publication number: 20170233481Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.Type: ApplicationFiled: May 3, 2017Publication date: August 17, 2017Applicant: AbbVie Biotherapeutics Inc.Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
-
Patent number: 9592293Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: December 9, 2013Date of Patent: March 14, 2017Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20160137732Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.Type: ApplicationFiled: June 27, 2014Publication date: May 19, 2016Inventors: Paul R. HINTON, Veronica JUAN
-
Publication number: 20150010539Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.Type: ApplicationFiled: March 14, 2014Publication date: January 8, 2015Applicant: AbbVie Biotherapeutics Inc.Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
-
Publication number: 20140377253Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.Type: ApplicationFiled: March 14, 2014Publication date: December 25, 2014Applicant: ABBVIE BIOTHERAPEUTICS INC.Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
-
Publication number: 20140186377Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.Type: ApplicationFiled: November 26, 2013Publication date: July 3, 2014Applicant: AbbVie, Inc.Inventors: Jijie Gu, Charles W. Hutchins, Rong-Rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Tariq Ghayur, Paul R. Hinton, Veronica M. Juan, John Mankovich, Junjian Liu
-
Publication number: 20140178332Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: January 13, 2014Publication date: June 26, 2014Applicant: ABBVIE INC.Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Publication number: 20140099313Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: ABBVIE INC.Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Maria A. ARGIRIADI, Hua YING, Carolyn A. CUFF, Terry L. MELIM, Shankar KUMAR, Paul R. HINTON, Yan CHEN
-
Patent number: 8629257Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: GrantFiled: April 19, 2010Date of Patent: January 14, 2014Assignee: Abbvie Inc.Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Patent number: 8624007Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.Type: GrantFiled: March 31, 2010Date of Patent: January 7, 2014Assignee: Abbvie Biotherapeutics Inc.Inventors: Paul R. Hinton, Naoya Tsurushita